TY - JOUR
T1 - Potential Impact and Study Considerations of Metabolomics in Cardiovascular Health and Disease
T2 - A Scientific Statement from the American Heart Association
AU - American Heart Association Council on Functional Genomics and Translational Biology
AU - Council on Cardiovascular and Stroke Nursing
AU - Council on Clinical Cardiology; and Stroke Council
AU - Cheng, Susan
AU - Shah, Svati H.
AU - Corwin, Elizabeth J.
AU - Fiehn, Oliver
AU - Fitzgerald, Robert L.
AU - Gerszten, Robert E.
AU - Illig, Thomas
AU - Rhee, Eugene P.
AU - Srinivas, Pothur R.
AU - Wang, Thomas J.
AU - Jain, Mohit
N1 - Publisher Copyright:
© 2017 American Heart Association, Inc.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Through the measure of thousands of small-molecule metabolites in diverse biological systems, metabolomics now offers the potential for new insights into the factors that contribute to complex human diseases such as cardiovascular disease. Targeted metabolomics methods have already identified new molecular markers and metabolomic signatures of cardiovascular disease risk (including branched-chain amino acids, select unsaturated lipid species, and trimethylamine-N-oxide), thus in effect linking diverse exposures such as those from dietary intake and the microbiota with cardiometabolic traits. As technologies for metabolomics continue to evolve, the depth and breadth of small-molecule metabolite profiling in complex systems continue to advance rapidly, along with prospects for ongoing discovery. Current challenges facing the field of metabolomics include scaling throughput and technical capacity for metabolomics approaches, bioinformatic and chemoinformatic tools for handling large-scale metabolomics data, methods for elucidating the biochemical structure and function of novel metabolites, and strategies for determining the true clinical relevance of metabolites observed in association with cardiovascular disease outcomes. Progress made in addressing these challenges will allow metabolomics the potential to substantially affect diagnostics and therapeutics in cardiovascular medicine.
AB - Through the measure of thousands of small-molecule metabolites in diverse biological systems, metabolomics now offers the potential for new insights into the factors that contribute to complex human diseases such as cardiovascular disease. Targeted metabolomics methods have already identified new molecular markers and metabolomic signatures of cardiovascular disease risk (including branched-chain amino acids, select unsaturated lipid species, and trimethylamine-N-oxide), thus in effect linking diverse exposures such as those from dietary intake and the microbiota with cardiometabolic traits. As technologies for metabolomics continue to evolve, the depth and breadth of small-molecule metabolite profiling in complex systems continue to advance rapidly, along with prospects for ongoing discovery. Current challenges facing the field of metabolomics include scaling throughput and technical capacity for metabolomics approaches, bioinformatic and chemoinformatic tools for handling large-scale metabolomics data, methods for elucidating the biochemical structure and function of novel metabolites, and strategies for determining the true clinical relevance of metabolites observed in association with cardiovascular disease outcomes. Progress made in addressing these challenges will allow metabolomics the potential to substantially affect diagnostics and therapeutics in cardiovascular medicine.
KW - AHA Scientific Statements
KW - cardiovascular diseases
KW - metabolome
KW - metabolomics
UR - http://www.scopus.com/inward/record.url?scp=85018752363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018752363&partnerID=8YFLogxK
U2 - 10.1161/HCG.0000000000000032
DO - 10.1161/HCG.0000000000000032
M3 - Article
C2 - 28360086
AN - SCOPUS:85018752363
SN - 1942-325X
VL - 10
JO - Circulation: Cardiovascular Genetics
JF - Circulation: Cardiovascular Genetics
IS - 2
M1 - e000032
ER -